Introduction {#sec1}
============

The Morita--Baylis--Hillman (MBH) reaction has gained renewed interest in organic synthesis as one of the atom-economical carbon--carbon bond forming reactions.^[@ref1]^ It provides the products having multifunctionalities which assist as handy precursors to access various heterocycles and carbocycles. Over the years, substantial efforts have been made for the utilization of MBH adducts and their derivatives toward the synthesis of several complex molecules including natural products and pharmaceuticals involving various reactions.^[@ref2]^ Despite these vast applications, the employment of MBH-adducts in Pauson--Khand reaction to access the cyclopentenones remains rare. For instance, Kamimura reported the intramolecular Pauson--Khand reaction of aza-Baylis--Hillman adducts (**A**) to obtain *cis*- and *trans*-pyrrolidine-fused cyclopentenones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}a).^[@cit3a]^ Our research group has demonstrated the sequential allylic substitution/Pauson--Khand reaction to access bicyclic fused cyclopentenones from MBH-acetates of acetylenic aldehydes (**B**, [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}b).^[@cit3b]^ Our interest is on the enyne-assisted annulations using MBH adducts;^[@ref4]^ we envisaged that the MBH adduct **C**, obtained from 2-alkynyl benzaldehyde, would be a suitable substrate to the intramolecular Pauson--Khand reaction generating the cyclopenta\[*a*\]inden-2(1*H*)-one (fused-cyclopentenone) having carboxylate functionality at the fused ring junction ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}c). It is also noteworthy to mention that the chemistry of MBH-adducts of 2-alkynyl benzaldehydes is less investigated.^[@ref5]^

![a--c) Intramolecular Pauson--Khand Reaction of MBH Derivatives](ao-2018-02111t_0003){#sch1}

On the other hand, cyclopenta\[*a*\]indene is an important structural motif present in biologically significant natural products as well as in pharmaceuticals ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref6]^ It also serves as a key intermediate toward the synthesis of bio-active naturally occurring molecules.^[@ref7]^ Interestingly, to our knowledge, there are presently few reports available for the synthesis of cyclopenta\[*a*\]inden-2(1*H*)-ones,^[@ref8]^ precisely with substitution/functionality at the fused ring junction (tert-carbon center).^[@ref9]^ The Pauson--Khand reaction, a carbonylative cyclization, is one of the commonly used approaches to construct the cyclopentenones.^[@ref10],[@ref11]^ However, the intramolecular Pauson--Khand reaction toward the synthesis of tricyclic cyclopenta\[*a*\]inden-2(1*H*)-ones has been less exploited.^[@ref12]^ Herein, we report the first direct access to cyclopenta\[*a*\]inden-2(1*H*)-one starting from readily accessible MBH products of 2-alkynyl benzaldehydes involving the intramolecular Pauson--Khand reaction as the key step.

![Representative compounds having cyclopenta\[*a*\]inden-2(1*H*)-one skeleton.](ao-2018-02111t_0001){#fig1}

Results and Discussion {#sec2}
======================

To investigate the envisaged Pauson--Khand reaction, we initially selected Morita Baylis--Hillman adduct **5a** (prepared from the corresponding 2-alkynyl benzaldehyde) as the model substrate and treated with Co~2~(CO)~8~ in 1,2-dichloroethane (DCE) at 80 °C ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}). To our delight, the reaction progressed well to afford the corresponding annulated product cyclopenta\[*a*\]inden-2(1*H*)-one, **6a** in 64% yield as single diastereomer. The stereochemistry of the major diastereomer was established as "cis" (relation between hydroxyl and carboxylate group) by X-ray crystal structure analysis ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, CCDC no. 1861746). The reaction scope was further extended to MBH adduct **5b** having n-propyl substitution on the alkyne, which provided the cyclopenta\[*a*\]indenone **6b** in 68% yield as single diastereomer ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"} & [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}, CCDC no. 1861745).

![X-ray crystal structure of **6a** and **6b** (ellipsoids are drawn at the 30% probability level.).](ao-2018-02111t_0002){#fig2}

![Pauson--Khand Reaction of MBH Alcohol **5**](ao-2018-02111t_0004){#sch2}

Encouraged by this finding, we studied the scope of amine-substituted MBH adducts ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), which were synthesized by allylic substitution of MBH carbonates (prepared by tert-butyloxycarbonylation of MBH-alcohol **5**). We employed the allylation of MBH carbonate **7a** with tosyl amine (TsNH~2~, **8a**) in the presence of 5 mol % of 1,4-diazabicyclo\[2.2.2\]octane (DABCO) to give amino MBH product **9a** in 94% yield. Next, compound **9a** was subjected to Pauson--Khand reaction using Co~2~(CO)~8~ in DCE at 80 °C and the formation of cyclopenta\[*a*\]indenone **10a** was observed in 78% yield as diastereomeric mixture (94:6). Other amino MBH substrates possessing an aliphatic R group on the alkyne, such as *n*-propyl (**9b**) and *tert*-butyloxy *n*-propyl (**9c**), also smoothly participated in the PK reaction to provide the corresponding cyclopenta\[*a*\]indenones **10b** and **10c** in 72 and 68% yields, respectively, with excellent diastereoselectivity (entry 2 and 3, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The cycloaddition reaction of MBH derivative **9d** with terminal alkyne was successful to give the indenone **10d** in 77% yield (entry 4). Afterward, the chemoselectivity in Pauson--Khand reaction with respect to two different olefins was verified through the reaction of *N*-allylamine derivative of MBH adduct **9e,** obtained by the treatment of **7a** with *N*-allyl-4-methylbenzenesulfonamide (**8b**). Gratifyingly, the reaction of **9e** offered exclusively the cyclopenta\[*a*\]indene-8a(1*H*)-carboxylate **10e** in 82% yield with excellent diastereoselectivity (entry 5, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}), wherein highly substituted olefin underwent the cycloaddition with alkyne favoring the formation of five-membered ring. Other substrates **9f** and **9g** also furnished the desired cyclopenta\[*a*\]indenones **10f** and **10g** in good yield, albeit with lower diastereoselectivity (entry 6 & 7, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The PK reaction of **9h** gave the cyclopenta\[*a*\]indenone **10h** in 81% yield with excellent diastereoselectivity (entry 8, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Further, other aza-MBH substrates **9i** with N-benzyl and **9j** having tert-butylsilyloxy groups (prepared from the reaction of **7a** with **8c** and **8d**, respectively) were also well participated in the intramolecular Pauson--Khand reaction to give the corresponding cyclopenta\[*a*\]indenones **10i** and **10j** with excellent diastereoselectivity (entry 9 & 10, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). The relative stereochemistry of the product **10e** and **10j** (CCDC nos. 1861747 and 1861744) was unequivocally assigned by X-ray crystallography.

###### Synthesis of Cyclopenta\[*a*\]indenones from Aza-MBH Derivatives

![](ao-2018-02111t_0007){#GRAPHIC-d7e546-autogenerated}

![](ao-2018-02111t_0008){#gr7}

To further expand the generality of the present method, the reactivity of MBH adduct **11** generated from 2-alkynyl pyridine 3-carboxaldehyde, was studied. Compound **11** was converted to the MBH carbonate **12** in 86% yield and subsequent substitution reaction of **12** with TsNH~2~ (**8a**) in the presence of DABCO in toluene provided the aza-MBH substrate **13** in 79% yield. Satisfactorily, the intramolecular PK reaction of **13** was successful to obtain the desired pentaleno\[1,2-*b*\]pyridin-7(5*H*)-one **14** in 82% yield with excellent diastereoselectivity ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Synthesis of Pentaleno\[1,2-*b*\]pyridin-7(5*H*)-one](ao-2018-02111t_0005){#sch3}

It was also possible to synthesize cyclopenta\[*a*\]inden-2(1*H*)-one **16** having electron-withdrawing group such as the cyano at the fused ring junction but in lower yield along with the decyanated product **17** as single diastereomer starting from the MBH adduct **15** (prepared from the reaction of acrylonitrile with corresponding 2-alkynyl benzaldehyde, [Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}).^[@cit5g]^ The stereochemistry of the product **16** was established as "cis" (relation between hydroxyl and cyano group) by X-ray crystal structure analysis (CCDC no. 1871966).

![Pauson--Khand Reaction of MBH Alcohol **15** Having CN Group](ao-2018-02111t_0006){#sch4}

Conclusion {#sec3}
==========

In summary, we disclosed the novel synthetic utility of readily accessible MBH adducts through the intramolecular Pauson--Khand reaction. This method provides a facile access to new cyclopenta\[*a*\]inden-2(1*H*)-one scaffolds in high yield and diastereoselectivity. A detailed study of substrate scope with respect to the substitution at both benzylic position (hydroxyl and diversely substituted amines) and alkyne functionality was done to establish the practicality of the strategy. Further derivatization of this cyclopenta\[*a*\]inden-2(1*H*)-ones and evaluation of their biological properties are actively in progress.

General Information {#sec4}
===================

Unless otherwise noted, all reagents were used as received from commercial suppliers. All nonaqueous reactions were performed under an atmosphere of nitrogen using oven-dried glassware and standard syringe in septa techniques. All solvents were dried before use following the standard procedures. Reactions were monitored using thin-layer chromatography (SiO~2~). Thin-layer chromatography (TLC) plates were visualized with UV light (254 nm), with iodine treatment, or using ninhydrin, anisaldehyde stain. Column chromatography was carried out using silica gel (100--200 mesh) packed in glass columns. NMR spectra were recorded at 300, 400, 500 MHz (H) and at 75, 101, 126 MHz (C), respectively. Chemical shifts (δ) are reported in ppm, using the residual solvent peak in CDCl~3~ (H: δ = 7.26 and C: δ = 77.16 ppm) as the internal standard, and coupling constants (*J*) are given in Hz. Mass spectra were obtained on VG 70--70H or LC/MSD trap SL spectrometer operating at 70 eV using direct inlet system. High-resolution mass spectra (HRMS) \[ESI^+^\] were obtained using either a TOF or a double-focusing spectrometer. X-ray data for the compounds were collected at room temperature using a Bruker Smart Apex CCD diffractometer with graphite monochromated Mo Kα radiation (λ = 0.71073 Å) with ω-scan method. The diastereomeric ratio was calculated based on the NMR spectra.

Experimental Section: Preparation of the 2-Alkynyl MBH Adducts {#sec5}
==============================================================

![](ao-2018-02111t_0010){#dgr1}

The 2-alkynyl benzaldehydes were prepared by using 2-bromobenzaldehyde with different terminal alkynes. The MBH adducts were prepared by known literature procedure.^[@ref5]^ Spectral data are given below.

General Procedure for Synthesis of **5** and **11** {#sec5.1}
---------------------------------------------------

A solution of 2-alkynylbenzaldehyde (1.0 equiv), methyl acrylate (3.0 equiv), and DABCO (1.0 equiv) was stirred in a round-bottom flask at room temperature until completion of reaction as monitored by TLC. Removal of solvent left crude reaction mixture, which was separated by column chromatography (hexane/EtOAc) on silica gel (100--200 mesh) to give the corresponding MBH adduct **5**, was done. All new products were fully characterized.

### Methyl 2-(Hydroxyl(2-(phenylethynyl)phenyl)methyl)acrylate (**5a**) {#sec5.1.1}

Colorless liquid (2.5 g, 84%). ^1^H NMR (500 MHz, CDCl~3~): δ 7.55 (dd, *J* = 16.9, 7.7 Hz, 2H), 7.49 (dd, *J* = 6.5, 3.1 Hz, 2H), 7.4--7.26 (m, 5H), 6.34 (s, 1H), 6.15 (d, *J* = 4.1 Hz, 1H), 5.68 (s, 1H), 3.75 (s, 3H), 3.26 (d, *J* = 4.8 Hz, 1H). ^13^C NMR (75 MHz, CDCl~3~): δ 167.1, 142.6, 141.3, 132.2, 131.5, 128.7, 128.5, 128.4, 127.7, 126.9, 126.4, 123.0, 121.7, 94.6, 87.1, 70.8, 52.1. IR (KBr): ν~max~ 3431, 2217, 1711, 1633, 1493, 1439 cm^--1^. MS (ESI): *m*/*z* 293 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~19~H~17~O~3~ (M + H)^+^, 293.1178; found, 293.1182.

### Methyl 2-(Hydroxy(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate (**5b**) {#sec5.1.2}

Colorless liquid (1.27 g, 85%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.49--7.45 (m, 1H), 7.40 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.30 (td, *J* = 7.6, 1.4 Hz, 1H), 7.22 (td, *J* = 7.5, 1.4 Hz, 1H), 6.32 (s, 1H), 6.04 (s, 1H), 5.62 (t, *J* = 1.2 Hz, 1H), 3.76 (s, 3H), 3.26 (s, 1H), 2.39 (t, *J* = 7.0 Hz, 2H), 1.67--1.56 (m, 2H), 1.06--0.99 (m, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 167.2, 142.3, 141.3, 132.3, 127.9, 127.5, 126.6, 126.3, 122.6, 95.8, 78.5, 70.7, 52.0, 22.1, 21.5, 13.5. IR (KBr): ν~max~ 3480, 2961, 2931, 2872, 2233, 1718, 1630, 1438, 1380, 1260, 1191, 1141, 1029, 956, 936, 834, 752, 666, 609 cm^--1^. MS (ESI): *m*/*z* 281 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~16~H~18~O~3~Na (M + Na)^+^, 281.1154; found, 281.1158.

### Methyl-2-((2-(5-((*tert*-butyldiphenylsilyl)oxy)pent-1-yn-yl)phenyl)(hydroxy)methyl)acrylate (**5c**) {#sec5.1.3}

Yellow liquid (2.16 g, 72%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.71--7.64 (m, 4H), 7.46 (d, *J* = 7.8 Hz, 1H), 7.43--7.34 (m, 6H), 7.32 (d, *J* = 11.2 Hz, 2H), 7.23--7.18 (m, 1H), 6.27 (d, *J* = 0.7 Hz, 1H), 5.99 (s, 1H), 5.61 (d, *J* = 1.2 Hz, 1H), 3.78 (t, *J* = 6.0 Hz, 2H), 3.70 (s, 3H), 3.14 (s, 1H), 2.58 (t, *J* = 7.1 Hz, 2H), 1.86--1.79 (m, 2H), 1.06 (s, 9H). ^13^C NMR (101 MHz, CDCl~3~): δ 167.1, 142.3, 141.2, 135.6, 133.8, 132.4, 129.6, 127.9, 127.7, 127.5, 126.6, 126.3, 122.5, 95.4, 78.5, 70.7, 62.4, 51.9, 31.6, 26.9, 19.3, 16.1. IR (KBr): ν~max~ 3506, 3070, 2952, 2931, 2857, 1720, 1589, 1439, 1427, 1360, 1190, 1105, 1029, 985, 938, 821, 750, 700, 666, 612 cm^--1^. MS (ESI): *m*/*z* 535 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~32~H~36~O~4~SiNa (M + Na)^+^, 535.2282; found, 535.2281.

### Methyl 2-((2-Ethynylphenyl)(hydroxyl)methyl)acrylate (**5d**) {#sec5.1.4}

Colorless liquid (800 mg, 79%). ^1^H NMR (500 MHz, CDCl~3~): δ 7.54--7.48 (m, 2H), 7.39 (td, *J* = 7.7, 1.3 Hz, 1H), 7.27 (ddd, *J* = 7.5, 6.7, 1.2 Hz, 1H), 6.34 (s, 1H), 6.07 (s, 1H), 5.66 (t, *J* = 1.1 Hz, 1H), 3.76 (s, 3H), 3.30 (s, 1H). ^13^C NMR (101 MHz, CDCl~3~): δ 167, 143.1, 141.1, 132.9, 129.2, 127.7, 126.8, 126.5, 120.8, 82.3, 81.4, 70.5, 52.1. ν~max~ 3435, 3280, 2104, 1715, 1629, 1435 cm^--1^. MS (ESI): *m*/*z* 239 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~13~H~12~NaO~3~Na (M + Na)^+^, 239.0679; found, 239.0671.

General Procedure for the Preparation of MBH-Carbonates (**7a--7d** and **12**) {#sec5.2}
-------------------------------------------------------------------------------

![](ao-2018-02111t_0011){#dgr2}

To a stirred solution of the corresponding MBH-alcohol (**5**) (1 equiv) in 10 mL of CH~2~Cl~2~ was added di*tert*-butyl dicarbonate (1.2 equiv) and DMAP (0.05 equiv) at 0 °C and stirred up to completion then, the mixture was diluted with water (50 mL) and extracted with CH~2~Cl~2~ (3 × 30 mL). The combined organic layer was dried over anhydrous Na~2~SO~4~ and concentrated in vacuo. The crude was purified by column chromatography on silica gel (EtOAc/hexane) to afford the corresponding MBH-carbonate. All these carbonates were fully characterized and spectral data are given below.

### Methyl 2-(((*tert*-Butoxycarbonyl)oxy)(2-(phenylethynyl)phenyl)methyl)acrylate (**7a**) {#sec5.2.1}

White solid (3.68 g, 91%). mp 80--83 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 7.55 (dt, *J* = 5.2, 4.4 Hz, 3H), 7.43--7.39 (m, 1H), 7.36--7.28 (m, 5H), 7.08 (s, 1H), 6.49 (s, 1H), 5.74 (s, 1H), 3.71 (s, 3H), 1.44 (s, 9H). ^13^C NMR (101 MHz, CDCl~3~): δ 165.6, 152.3, 139.1, 138.8, 132.4, 131.7 (2C), 128.4, 128.3 (2C), 127.9, 126.6, 123.1, 122.9, 94.9, 86.6, 82.7, 73.9, 52.1, 27.9. IR (KBr): ν~max~ 2982, 1744, 1600, 1477, 1370, 1249, 1117, 961, 845, 749, 666 cm^--1^. MS (ESI): *m*/*z* 415 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~24~H~24~NaO~5~Na (M + Na)^+^, 415.1516; found, 415.1552.

### Methyl 2-(((*tert*-Butoxycarbonyl)oxy)(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate (**7b**) {#sec5.2.2}

Colorless liquid (1.19 g, 86%). ^1^H NMR (300 MHz, CDCl~3~): δ 7.45--7.39 (m, 1H), 7.37--7.33 (m, 1H), 7.31--7.21 (m, 2H), 6.96 (s, 1H), 6.45 (s, 1H), 5.62 (s, 1H), 3.75 (s, 3H), 2.39 (t, *J* = 7.0 Hz, 2H), 1.60 (dd, *J* = 8.5, 5.9 Hz, 2H), 1.47 (s, 9H), 1.02 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 165.6, 152.4, 138.9, 138.8, 132.3, 128.1, 127.8, 127.6, 126.4, 123.6, 96.1, 82.4, 77.9, 73.9, 52.0, 27.7, 22.1, 21.6, 13.6. IR (KBr): ν~max~ 2956, 2854, 1746, 1729, 1369, 1248, 1154, 961, 870, 756, 701, 613 cm^--1^. MS (ESI): *m*/*z* 381 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~21~H~26~ O~5~Na (M + Na)^+^, 381.1678; found, 381.1680.

### Methyl-2-(((*tert*-butoxycarbonyl)oxy)(2-(5-((*tert*-butyldiphenylsilyl)oxy)pent-1-yn-1-yl)phenyl)methyl)acrylate (**7c**) {#sec5.2.3}

Brown liquid (1.93 g, 75%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.70--7.64 (m, 4H), 7.43--7.32 (m, 8H), 7.30--7.20 (m, 2H), 6.94 (s, 1H), 6.40 (s, 1H), 5.62 (dd, *J* = 3.6, 2.6 Hz, 1H), 3.81--3.74 (m, 2H), 3.70--3.64 (s, 3H), 2.57 (t, *J* = 7.2 Hz, 2H), 1.84 (pd, *J* = 7.6, 3.7 Hz, 2H), 1.45 (s, 9H), 1.09--1.02 (m, 9H). ^13^C NMR (101 MHz, CDCl~3~): δ 165.6, 152.4, 138.9, 138.8, 135.6, 133.9, 132.4, 129.6, 128.1, 127.9, 127.7, 126.4, 123.6, 95.8, 82.5, 77.9, 73.9, 62.6, 52.0, 31.7, 27.8, 26.9, 19.3, 16.2. IR (KBr): ν~max~ 2931, 2857, 1748, 1429, 1275, 1109, 962, 704. MS (ESI): *m*/*z* 635 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~37~H~44~O~6~SiNa (M + Na)^+^, 635.2799; found, 635.2820.

### Methyl 2-(((*tert*-Butoxycarbonyl)oxy)(2-ethynylphenyl)methyl)acrylate (**7d**) {#sec5.2.4}

Colorless liquid (1.02 g, 88%). ^1^H NMR (500 MHz, CDCl~3~): δ 7.52 (dd, *J* = 7.6, 1.0 Hz, 1H), 7.40--7.33 (m, 2H), 7.31--7.26 (m, 1H), 6.96 (s, 1H), 6.46 (s, 1H), 5.71--5.65 (s, 1H), 3.74 (s, 3H), 3.32 (s, 1H), 1.47 (s, 9H). ^13^C NMR (126 MHz, CDCl~3~): δ 165.4, 152.3, 139.7, 138.6, 133.1, 129.1, 128.2, 127.8, 126.8, 121.8, 82.6, 82.6, 80.7, 73.7, 52.1, 27.7. IR (KBr): ν~max~ 3302, 2982, 1727, 1370, 1251, 1153, 962, 845, 748, 666 cm^--1^. MS (ESI): *m*/*z* 339 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~18~H~21~O~5~ (M + H)^+^, 317.1384; found, 317.1367.

General Procedure for the Synthesis of Intermediate (**9a--9j** and **13**) {#sec5.3}
---------------------------------------------------------------------------

To a stirred solution of the corresponding MBH-carbonate **7** (1 equiv) in 2 mL of toluene was added amine **8** (0.8 equiv) and DABCO (0.05 equiv) at 0 °C and stirred up to completion. Then, the removal of solvent left crude, which was purified by column chromatography on silica gel (100--200 mesh), (EtOAc/hexane) to afford the corresponding aminated MBH adduct **9**. All these compounds were fully characterized by obtaining spectral data.

### Methyl-2-(((4-methylphenyl)sulfonamido)(2-(phenylethynyl)phenyl)methyl)acrylate (**9a**) {#sec5.3.1}

Yellow liquid (106 mg, 94%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.62 (d, *J* = 8.3 Hz, 2H), 7.51 (dq, *J* = 7.6, 2.4 Hz, 2H), 7.43--7.36 (m, 4H), 7.33--7.28 (m, 1H), 7.20--7.15 (m, 2H), 7.07 (d, *J* = 8.1 Hz, 2H), 6.24 (s, 1H), 5.89 (d, *J* = 14.6 Hz, 3H), 3.61 (s, 3H), 2.29 (s, 3H). ^13^C NMR (126 MHz, CDCl~3~): δ 165.9, 143.1, 139.8, 138.6, 137.3, 132.6, 131.6, 129.3, 128.7, 128.5 (2C), 128.1, 127.5, 127.4, 127.2, 122.8, 121.7, 95.2, 87.2, 56.9, 52.0, 21.4. IR (KBr): ν~max~ 3277, 2951, 2923, 1721, 1598, 1329, 1193, 1155, 1060, 915, 811, 753, 664 cm^--1^. MS (ESI): *m*/*z* (M + Na)^+^ 468.30; HRMS (ESI): *m*/*z* calcd for C~26~H~24~NO~4~S (M + H)^+^, 446.1421; found, 446.1430.

### Methyl 2-(((4-Methylphenyl)sulfonamido)(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate (**9b**) {#sec5.3.2}

Pale yellow solid (99 mg, 87%). mp 90--92 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 7.59 (d, *J* = 8.3 Hz, 2H), 7.28--7.26 (m, 1H), 7.19 (dd, *J* = 7.2, 1.8 Hz, 1H), 7.13--7.05 (m, 4H), 6.21 (s, 1H), 5.94 (d, *J* = 9.3 Hz, 1H), 5.85--5.74 (m, 2H), 3.63 (s, 3H), 2.40 (t, *J* = 7.1 Hz, 2H), 2.34 (s, 3H), 1.69--1.59 (m, 2H), 1.06 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (126 MHz, CDCl~3~): δ 166, 143, 139.2, 138.4, 137.6, 132.8, 129.2, 127.7, 127.6, 127.5, 127.3, 127.1, 122.4, 96.7, 78.7, 57.2, 51.9, 22.1, 21.6, 21.4, 13.7. IR (KBr): ν~max~ 3282, 3020, 2872, 2232, 1724, 1483, 1214, 1159, 1063, 918, 813, 753, 667 cm^--1^. MS (ESI): *m*/*z* 434 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~23~H~25~NO~4~SNa (M + Na)^+^, 434.1402; found, 434.1402.

### Methyl-2-((2-(5-((*tert*-butyldiphenylsilyl)oxy)pent-1-yn-1-yl)phenyl)(4-methylphenyl sulfonamido) methyl)acrylate (**9c**) {#sec5.3.3}

Pale yellow solid (89 mg, 82%). mp 85--87 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 7.68 (dt, *J* = 7.5, 3.7 Hz, 4H), 7.57 (d, *J* = 8.3 Hz, 2H), 7.43--7.34 (m, 6H), 7.24--7.16 (m, 2H), 7.08 (ddd, *J* = 6.4, 4.8, 3.0 Hz, 4H), 6.17 (s, 1H), 5.81 (s, 1H), 5.81--5.73 (m, 2H), 3.79 (t, *J* = 5.9 Hz, 2H), 3.60 (s, 3H), 2.58 (t, *J* = 7.3 Hz, 2H), 2.31 (s, 3H), 1.89--1.82 (m, 2H), 1.07 (s, 9H). ^13^C NMR (126 MHz, CDCl~3~): δ 166, 143, 139.2, 138.3, 137.6, 135.6, 133.8, 132.9, 129.6, 129.2, 127.7, 127.7, 127.6, 127.4, 127.3, 127.1, 122.3, 96.4, 78.7, 62.5, 57.3, 51.9, 31.6, 26.9, 21.4, 19.3, 16.2. IR (KBr): ν~max~ 2931, 1726, 1428, 1332, 1262, 1157, 1109, 704. MS (ESI): *m*/*z* 688 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~39~H~43~NNaO~5~SSi (M + Na)^+^, 688.2523; found, 688.2546.

### Methyl 2-((2-Ethynylphenyl)(4-methylphenylsulfonamido)methyl)acrylate (**9d**) {#sec5.3.4}

White solid (92 mg, 79%). mp 143--145 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 7.65--7.60 (m, 2H), 7.37 (dd, *J* = 7.4, 1.6 Hz, 1H), 7.26 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.22--7.10 (m, 4H), 6.26 (s, 1H), 5.93 (s, 1H), 5.84 (d, *J* = 19.2 Hz, 1H), 5.81 (d, *J* = 8.9 Hz, 1H), 3.63 (s, 3H), 3.27 (s, 1H), 2.35 (s, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 165, 142.1, 139.2, 136.9, 136.4, 132.3, 128.2, 127.9, 127.2, 126.4, 126.4, 126.2, 119.6, 82.2, 80.3, 56, 51, 20.4. IR (KBr): ν~max~ 2958, 2858, 1730, 1554, 1365, 1257, 1172, 759. MS (ESI): *m*/*z* 392 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~20~H~19~NO~4~SNa (M + Na)^+^, 392.0927; found, 392.0932.

### Methyl 2-(((*N*-Allyl-4-methylphenyl)sulfonamido)(2-(phenylethynyl)phenyl)methyl)acrylate (**9e**) {#sec5.3.5}

Pale yellow liquid (117 mg, 95%).^1^H NMR (500 MHz, CDCl~3~): δ 7.54 (d, *J* = 8.3 Hz, 2H), 7.46--7.43 (m, 2H), 7.42--7.38 (m, 1H), 7.30--7.24 (m, 4H), 7.20--7.15 (m, 2H), 7.05 (d, *J* = 8.1 Hz, 2H), 6.53 (s, 1H), 6.43 (s, 1H), 5.53 (d, *J* = 1.0 Hz, 1H), 5.48--5.36 (m, 1H), 4.85--4.75 (m, 2H), 3.95 (d, *J* = 6.3 Hz, 2H), 3.45 (s, 3H), 2.29 (s, 3H). ^13^C NMR (126 MHz, CDCl~3~): δ 166.1, 142.8, 140.1, 139, 138.1, 134.2, 132.7, 131.7, 130.3, 129.1, 128.4, 128.3, 128.3, 128.2, 127.8, 127.6, 123.1, 123.1, 117.5, 95.2, 87.3, 60.6, 51.9, 50.3, 21.3. IR (KBr): ν~max~ 3021, 2951, 1721, 1598, 1493, 1339, 1156, 1089, 928, 811, 747, 665 cm^--1^. MS (ESI): *m*/*z* 508 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~29~H~27~NO~4~SNa (M + Na)^+^, 508.1553; found, 508.1537.

### Methyl 2-(((*N*-Allyl-4-methylphenyl)sulfonamido)(2-(pent-1-yn-1-yl)phenyl)methyl)acrylate (**9f**) {#sec5.3.6}

Colorless liquid (112 mg, 89%).^1^H NMR (400 MHz, CDCl~3~): δ 7.51 (d, *J* = 8.3 Hz, 2H), 7.30--7.19 (m, 1H), 7.21--7.14 (m, 1H), 7.13--7.05 (m, 4H), 6.40 (d, *J* = 11.7 Hz, 2H), 5.50--5.38 (m, 2H), 4.85--4.77 (m, 2H), 3.91 (d, *J* = 6.3 Hz, 2H), 3.50 (s, 3H), 2.33--2.28 (m, 5H), 1.52 (dd, *J* = 14.4, 7.2 Hz, 2H), 0.94 (t, *J* = 7.4 Hz, 3H). ^13^C NMR (126 MHz, CDCl~3~): δ 166.1, 142.8, 139.7, 139.1, 138.1, 134.4, 132.6, 129.9, 129.1, 128.1, 127.7, 127.4, 127.3, 124.1, 117.4, 96.6, 78.5, 60.5, 51.8, 50.3, 22.1, 21.7, 21.5, 13.6. IR (KBr): ν~max~ 3021, 2925, 2853, 2234, 1724, 1598, 1341, 1158, 1090, 929, 755, 666 cm^--1^. MS (ESI): *m*/*z* 474 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~26~H~29~NO~4~SNa (M + Na)^+^, 474.1715; found, 474.1711.

### Methyl 2-(((*N*-Allyl-4-methylphenyl)sulfonamido)(2-(5-((*tert*-butyldiphenylsilyl)oxy)pent-1-yn-1-yl)phenyl)methyl)acrylate (**9g**) {#sec5.3.7}

Colorless liquid (89 mg, 78%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.67 (d, *J* = 6.4 Hz, 4H), 7.57 (d, *J* = 8.3 Hz, 2H), 7.43--7.33 (m, 6H), 7.29 (dd, *J* = 6.1, 3.0 Hz, 1H), 7.25--7.22 (m, 1H), 7.19--7.12 (m, 4H), 6.46 (s, 1H), 6.41 (s, 1H), 5.49 (dd, *J* = 10.8, 6.2 Hz, 2H), 4.90--4.80 (m, 2H), 3.96 (d, *J* = 6.3 Hz, 2H), 3.75 (t, *J* = 6.0 Hz, 2H), 3.51 (s, 3H), 2.55 (q, *J* = 7.5 Hz, 2H), 2.35 (s, 3H), 1.82 (dd, *J* = 13.7, 6.8 Hz, 2H), 1.05 (s, 9H). ^13^C NMR (101 MHz, CDCl~3~): δ 166.1, 142.8, 139.7, 139.1, 138.1, 135.6, 134.4, 133.8, 132.6, 129.9, 129.6, 129.1, 128.1, 127.7, 127.4, 124.1, 117.5, 96.3, 78.6, 62.6, 60.5, 51.9, 50.3, 31.5, 26.9, 21.5, 19.3, 16.3. IR (KBr): ν~max~ 3070, 2930, 1723, 1598, 1428, 1342, 1260, 1156, 1090, 935, 811, 700, 660 cm^--1^. MS (ESI): *m*/*z* 728 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~42~H~47~NO~5~SSiNa (M + Na)^+^, 728.2836; found, 728.2871.

### Methyl 2-(((*N*-Allyl-4-methylphenyl)sulfonamido)(2-ethynylphenyl)methyl)acrylate (**9h**) {#sec5.3.8}

White solid (115 mg, 89%). mp 90--92 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 7.61--7.56 (m, 2H), 7.41 (dd, *J* = 7.5, 1.4 Hz, 1H), 7.33--7.30 (m, 1H), 7.29--7.19 (m, 2H), 7.17 (d, *J* = 8.0 Hz, 2H), 6.50 (s, 1H), 6.46 (s, 1H), 5.62 (d, *J* = 1.2 Hz, 1H), 5.50 (ddt, *J* = 16.5, 10.2, 6.3 Hz, 1H), 4.93--4.83 (m, 2H), 4.02--3.99 (m, 2H), 3.59 (s, 3H), 3.25 (s, 1H), 2.39 (s, 3H). ^13^C NMR (126 MHz, CDCl~3~): δ 166.1, 142.9, 140.4, 139.1, 138, 134.3, 133.3, 129.9, 129.1, 128.7, 128.4, 127.7, 127.6, 122.2, 117.6, 83.2, 81.3, 60.4, 52.1, 50.4, 21.5. IR (KBr): ν~max~ 3300, 3023, 1720, 1439, 1337, 1214, 1153, 1033, 933, 743, 663 cm^--1^. MS (ESI): *m*/*z* 432 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~23~H~23~NO~4~SNa (M + Na)^+^, 432.1240; found, 432.1280.

### Methyl-2-((*N*-((*tert*-butyldimethylsilyl)oxy)-4-methylphenylsulfonamido)(2(phenylethynyl)-phenyl)methyl)acrylate (**9i**) {#sec5.3.9}

White solid (124 mg, 85%); mp 152--154 °C; ^1^H NMR (500 MHz, CDCl~3~): δ 7.75--7.64 (m, 3H), 7.48 (s, 3H), 7.35 (s, 3H), 7.23--7.16 (m, 2H), 7.06 (d, *J* = 7.1 Hz, 2H), 6.59 (s, 1H), 6.33 (s, 1H), 5.25 (s, 1H), 3.47 (s, 3H), 2.32 (s, 3H), 0.95 (s, 9H), 0.36 (s, 3H), 0.17 (s, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 166.3, 143, 139.7, 137.9, 132.4, 132.1, 131.8, 131.2, 130.2, 129.2, 128.9, 128.4, 128.2, 127.9, 127.2, 123.1, 122.4, 94.8, 86.9, 63.1, 51.8, 26.4, 21.5, 18.6, −3.6, −3.7. IR (KBr): ν~max~ 2958, 2858, 1913, 1730, 1365, 1172, 812 cm^--1^. MS (ESI): *m*/*z* 598 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~32~H~37~NO~5~SSiNa (M + Na)^+^, 598.2065; found, 598.2059.

### Methyl-2-((*N*-benzyl-4-methylphenylsulfonamido)(2-(phenylethynyl)phenyl)methyl)acrylate (**9j**) {#sec5.3.10}

Colorless liquid (129 mg, 95%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.54--7.45 (m, 4H), 7.38--7.29 (m, 5H), 7.18--7.13 (m, 4H), 7.13--7.05 (m, 5H).6.54 (s, 1H), 6.36 (s, 1H), 5.55 (d, *J* = 0.9 Hz, 1H), 4.71 (s, 2H), 3.42 (s, 3H), 2.34 (s, 3H). ^13^C NMR (126 MHz, CDCl~3~): δ 166, 142.8, 140.1, 138.5, 138.1, 136.7, 132.4, 131.6, 131.1, 129.1, 128.6, 128.5, 128.4, 128.4, 128.1, 128.1, 127.6, 127.3, 127.2, 123.1, 122.9, 95.1, 87.4, 61.1, 52.6, 51.7. IR (KBr): ν~max~ 3062, 3027, 2949, 1721, 1598, 1493, 1339, 1155, 1029, 925, 811, 754, 666 cm^--1^. MS (ESI): *m*/*z* 558 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~33~H~29~NO~4~SNa (M + Na)^+^, 558.1715; found, 558.1718.

General Experimental Procedure for Pauson--Khand Reaction (**6a**, **6b**, **10a--10j** and **14**) {#sec5.4}
---------------------------------------------------------------------------------------------------

To a stirred solution of compound **5** or **9** or **13** (1 equiv) in DCE (5 mL) at room temperature was added Co~2~(CO)~8~ (1.1 equiv), and the mixture was stirred at room temperature until the consumption of the Co~2~(CO)~8~--eneyne complex (monitored by TLC, 2 h). Then, it was heated to 80 °C till completion (monitored by TLC). The reaction mixture was filtered through a Celite pad, and solvent was evaporated to get crude reaction mixture, which was purified by silica gel (100--200 mesh) column chromatography to obtain the corresponding cyclopenta\[*a*\]inden-2(1*H*)-one **6** or **10** or **14**.

### Methyl 8-Hydroxy-2-oxo-3-phenyl-1,2,8,8a-tetrahydrocyclopenta\[*a*\]indene-8a-carboxylate (**6a**) {#sec5.4.1}

Pale yellow solid (69 mg, 64%); mp 147--149 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.69 (d, *J* = 7.7 Hz, 1H), 7.58 (d, *J* = 7.6 Hz, 1H), 7.51--7.32 (m, 6H), 7.26 (t, *J* = 7.6 Hz, 1H), 5.43 (d, *J* = 5.3 Hz, 1H), 3.55 (s, 3H), 3.06 (d, *J* = 17.0 Hz, 1H), 2.89 (d, *J* = 17.0 Hz, 1H), 1.85 (d, *J* = 6.2 Hz, 1H). ^13^C NMR (101 MHz, CDCl~3~): δ 204.9, 171.7, 168.6, 148.1, 136.5, 132.9, 131.74, 129.5, 128.9, 128.4, 127.9, 127.4, 125.5, 123.6, 72.1, 64, 52.1, 41.1. IR (KBr): ν~max~ 3450. 3017, 1708, 1348, 1244, 1021, 757. MS (ESI): *m*/*z* 343 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~20~H~16~O~4~Na (M + H)^+^, 343.0941; found, 343.0944.

### Methyl 8-Hydroxy-2-oxo-3-propyl-1,2,8,8a-tetrahydrocyclopenta\[*a*\]indene-8a-carboxylate (**6b**) {#sec5.4.2}

White solid, (75 mg, 68%); mp 117--119 °C; ^1^H NMR (300 MHz, CDCl~3~): δ 7.57 (dt, *J* = 16.7, 7.5 Hz, 3H), 7.41 (t, *J* = 7.5 Hz, 1H), 5.06 (d, *J* = 12.0 Hz, 1H), 4.45 (d, *J* = 11.9 Hz, 1H), 3.63 (s, 3H), 3.10 (d, *J* = 17.3 Hz, 1H), 2.70 (d, *J* = 17.2 Hz, 1H), 2.44 (dtd, *J* = 20.6, 13.4, 7.5 Hz, 2H), 1.59 (dd, *J* = 14.0, 7.1 Hz, 2H), 0.93 (t, *J* = 7.3 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 207.3, 174.0, 167.3, 149.2, 136.1, 132.5, 131.9, 128.9, 124.2 (2C), 80.3, 66.2, 53.1, 45.1, 25.5, 21.7, 13.8. IR (KBr): ν~max~ 3479, 3019, 2922, 2852, 1708, 1435, 1214, 784. MS (ESI): *m*/*z* 309 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~17~H~18~O~4~Na (M + Na)^+^, 309.1112; found, 309.1103.

### Methyl 8-((4-Methylphenyl)sulfonamido)-2-oxo-3-phenyl-2,8-dihydrocyclopenta\[*a*\]indene-8a(1*H*)-arboxylate (**10a**) {#sec5.4.3}

Pale yellow solid (87 mg, 78%); mp 190--192 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.83 (d, *J* = 8.3 Hz, 2H), 7.61 (d, *J* = 7.7 Hz, 1H), 7.50--7.39 (m, 7H), 7.36 (d, *J* = 8.0 Hz, 2H), 7.28--7.22 (m, 1H).6.49 (d, *J* = 10.6 Hz, 1H), 4.92 (d, *J* = 10.6 Hz, 1H), 3.61 (s, 3H), 2.66 (d, *J* = 17.2 Hz, 1H), 2.52--2.45 (m, 4H). ^13^C NMR (101 MHz, CDCl~3~): δ 204.8, 172.3, 167.5, 146.7, 144.2, 137.9, 135.0, 132.9, 132.1, 130.0, 129.9, 129.2, 129.0, 128.9, 128.4, 127.1, 124.3, 124.1, 65.9, 62.7, 53.4, 45.7, 21.7. IR (KBr): ν~max~ 3274, 2922, 1705, 1433, 1157, 1081, 747, 663 cm^--1^. MS (ESI): *m*/*z* 496 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~27~H~24~NO~5~S (M + H)^+^, 474.1370; found, 474.1355.

### Methyl 8-((4-Methylphenyl)sulfonamido)-2-oxo-3-propyl-2,8-dihydrocyclopenta\[*a*\]indene-8a(1*H*)-carboxylate (**10b**) {#sec5.4.4}

White solid (76 mg, 72%); mp 148--150 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.80 (d, *J* = 8.1 Hz, 2H), 7.55--7.31 (m, 6H), 6.50 (d, *J* = 10.6 Hz, 1H), 4.80 (d, *J* = 10.6 Hz, 1H), 3.55 (s, 3H), 2.51--2.39 (m, 5H), 2.35--2.21 (m, 2H), 1.48 (s, 2H), 0.91 (dt, *J* = 14.7, 7.3 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 206.7, 172.5, 167.3, 146.3, 144.0, 137.9, 136.4, 132.5, 132.0 (2C), 129.9, 129.1, 127.1, 124.4, 124.3, 65.8, 62.7, 53.1, 45.2, 27.9, 25.4, 21.6, 13.7. IR (KBr): ν~max~ 3292, 3020, 2959, 2932, 2871, 1707, 1649, 1598, 1493, 1215, 1161, 930, 815, 753, 664 cm^--1^. MS (ESI): *m*/*z* 440 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~24~H~26~NO~5~S (M + H)^+^, 440.1526; found, 440.1528.

### Methyl 3-(3-((*tert*-Butyldiphenylsilyl)oxy)propyl)-8-((4-methylphenyl)sulfonamido)-2-oxo-2,8-dihydro-cyclopenta\[*a*\]indene-8a(1*H*)-carboxylate (**10c**) {#sec5.4.5}

White solid (63 mg, 68%); mp 145--147 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.80 (d, *J* = 8.3 Hz, 2H), 7.65--7.60 (m, 5H), 7.47--7.38 (m, 4H), 7.37--7.32 (m, 6H), 7.27--7.25 (m, 1H), 6.48 (d, *J* = 10.6 Hz, 1H), 4.78 (d, *J* = 10.6 Hz, 1H), 3.64 (t, *J* = 5.9 Hz, 2H), 3.50 (s, 3H), 2.56 (dd, *J* = 11.3, 4.7 Hz, 2H), 2.47--2.39 (m, 4H), 2.22 (d, *J* = 17.2 Hz, 1H), 1.78--1.62 (m, 2H), 1.06 (s, 9H). ^13^C NMR (126 MHz, CDCl~3~): δ 206.6, 172.5, 167.5, 146.2, 144.1, 137.9, 136.1, 135.5, 135.5, 133.7, 133.7, 132.4, 132.1, 129.9, 129.7, 129.1, 127.7, 127.1, 124.8, 124.2, 65.8, 63.1, 62.7, 53.1, 45.3, 31.1, 26.9, 21.7, 20.1, 19.3. IR (KBr): ν~max~ 3295, 2955, 2924, 2854, 1708, 1650, 1599, 1427, 1339, 1215, 1091, 1028, 934, 815, 752, 663 cm^--1^. MS (ESI): *m*/*z* 716 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~40~H~43~NO~6~SSiNa (M + Na)^+^, 716.2473; found, 716.2508.

### Methyl 8-(4-Methylphenylsulfonamido)-2-oxo-1,2,8,8a-tetrahydrocyclopenta\[*a*\]indene-8a-carboxylate (**10d**) {#sec5.4.6}

Pale yellow solid (76 mg, 77%); mp 199--201 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.75--7.71 (m, 2H), 7.44 (ddd, *J* = 8.7, 5.4, 1.7 Hz, 2H), 7.37--7.30 (m, 2H), 7.27 (d, *J* = 7.9 Hz, 2H), 6.40 (d, *J* = 10.7 Hz, 1H), 6.13 (s, 1H), 4.77 (d, *J* = 10.7 Hz, 1H), 3.51 (s, 3H), 2.42--2.36 (m, 4H), 2.25 (d, *J* = 17.1 Hz, 1H). ^13^C NMR (101 MHz, CDCl~3~): δ 206.5, 174.9, 171.8, 146.5, 144.1, 137.8, 133.1, 131.8, 129.9, 129.3, 127.1, 124.4, 124.3, 122.2, 67.8, 62.6, 53.3, 46.2, 21.7. IR (KBr): ν~max~ 3019, 2955, 1708, 1625, 1434, 1215, 1160, 1029, 896, 814, 743, 661 cm^--1^. MS (ESI): *m*/*z* 398 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~21~H~19~NO~5~SNa (M + Na)^+^, 420.0882; found, 420.0873.

### Methyl 8-((*N*-Allyl-4-methylphenyl)sulfonamido)-2-oxo-3-phenyl-2,8-dihydrocyclopenta\[*a*\]indene-8a(1*H*)-carboxylate (**10e**) {#sec5.4.7}

White solid (101 mg, 82%); mp 142--144 °C; ^1^H NMR (500 MHz, CDCl~3~): δ 7.80 (d, *J* = 8.3 Hz, 2H), 7.70 (d, *J* = 7.7 Hz, 1H), 7.50--7.44 (m, 4H), 7.40 (ddd, *J* = 6.4, 3.8, 1.8 Hz, 1H), 7.33 (dd, *J* = 9.7, 7.5 Hz, 3H), 7.25--7.20 (m, 1H), 6.76 (d, *J* = 7.6 Hz, 1H), 5.84 (ddd, *J* = 15.3, 10.1, 4.9 Hz, 1H), 5.72 (s, 1H), 5.13 (ddd, *J* = 13.8, 11.5, 1.2 Hz, 2H), 3.90 (d, *J* = 5.7 Hz, 2H), 3.60 (s, 3H), 3.51 (d, *J* = 17.6 Hz, 1H), 2.95 (d, *J* = 17.7 Hz, 1H), 2.46 (s, 3H); ^13^C NMR (101 MHz, CDCl~3~): δ 204.6, 170.9, 168.1, 144.1, 142.8, 135.7, 129.8, 129.7, 128.9, 128.9, 128.4, 127.7, 116.8, 77.4, 77.1, 76.8, 70.2, 65.9, 53.2, 48.9, 46.3, 21.6. IR (KBr): ν~max~ 1704, 1343, 1156, 1089, 1024, 921, 735, 661 cm^--1^. MS (ESI): *m*/*z* 536 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~30~H~27~NO~5~SNa (M + Na)^+^, 536.1502; found, 536.1493.

### Methyl 8-(*N*-Allyl-4-methylphenylsulfonamido)-2-oxo-3-propyl-1,2,8,8a-tetrahydrocyclopenta\[*a*\]indene-8a-carboxylate (**10f**) {#sec5.4.8}

White solid (92 mg, 78%); mp 138--140 °C; ^1^H NMR (500 MHz, CDCl~3~): δ 7.84 (d, *J* = 8.1 Hz, 2H), 7.62 (t, *J* = 8.4 Hz, 1H), 7.46--7.29 (m, 4H), 7.01 (d, *J* = 7.5 Hz, 1H), 6.00 (s, 1H), 5.87--5.78 (m, 1H), 5.11 (dd, *J* = 24.7, 13.7 Hz, 2H), 3.58 (s, 3H), 3.32 (d, *J* = 17.6 Hz, 1H), 3.25 (d, *J* = 6.5 Hz, 2H), 2.57 (d, *J* = 17.6 Hz, 1H), 2.46 (s, 3H), 2.37--2.25 (m, 2H), 1.62--1.52 (m, 2H), 0.93 (dd, *J* = 14.1, 7.1 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 207.4, 172.7, 170.1, 144.2, 137.9, 136.8, 135.7, 134.3, 131.7, 130, 127.7, 124.8, 117.3, 70.2, 62.4, 53.2, 48.9, 45.7, 25.6, 21.7, 13.9 IR (KBr): ν~max~ 3020, 2927, 2852, 1731, 1706, 1435, 1215, 1160, 1023, 894, 750, 661 cm^--1^. MS (ESI): *m*/*z* 502 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~27~H~29~NO~5~SNa (M + Na)^+^, 502.1659; found, 502.1637.

### Methyl 8-(*N*-Allyl-4-methylphenylsulfonamido)-3-(3-((*tert*-butyldiphenylsilyl)oxy)propyl)-2-oxo-1,2,8,8a-tetrahydrocyclopenta\[*a*\]indene-8a-carboxylate (**10g**) {#sec5.4.9}

Colorless liquid (59 mg, 64%). ^1^H NMR (500 MHz, CDCl~3~): δ 7.85 (s, 1H), 7.79--7.76 (m, 1H), 7.65 (d, *J* = 3.4 Hz, 3H), 7.36 (tt, *J* = 5.2, 3.0 Hz, 11H), 7.29 (d, *J* = 7.5 Hz, 1H), 7.00 (d, *J* = 7.6 Hz, 1H), 6.00 (s, 1H), 5.37--5.28 (m, 1H), 5.11 (dd, *J* = 23.5, 13.8 Hz, 1H), 4.63 (d, *J* = 10.5 Hz, 1H), 4.37 (d, *J* = 17.0 Hz, 1H), 3.87 (d, *J* = 5.7 Hz, 1H), 3.73--3.68 (m, 2H), 3.52 (s, 3H), 2.63--2.56 (m, 3H), 2.55 (d, *J* = 6.1 Hz, 1H), 2.49 (s, 3H), 1.79--1.70 (m, 2H), 1.09 (s, 9H). ^13^C NMR (126 MHz, CDCl~3~): δ 207.2, 172.7, 170.3, 144.1, 144, 143.9, 142.4, 137.7, 137.4, 135.8, 135.7, 135.6, 135.4, 134.3, 133.8, 133.7, 131.7, 131.1, 130.1, 130, 129.8, 129.67, 129.1, 127.7, 127.6, 127.3, 125.1, 117.3, 116.7, 70.3, 65.9, 63.2, 63.1, 62.4, 62.1, 53.2, 53.1, 51.9, 48.9, 47.9, 45.8, 42.9, 31.2, 31.1, 29.7, 26.9, 21.7, 20.3, 20.1, 19.3. IR (KBr): ν~max~ 3019, 2928, 2856, 1707, 1428, 1215, 1089, 931, 747, 663 cm^--1^. MS (ESI): *m*/*z* 756 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~43~H~48~NO~6~SSi (M + H)^+^, 734.2972; found, 734.2976.

### Methyl 8-((*N*-Allyl-4-methylphenyl)sulfonamido)-2-oxo-2,8-dihydrocyclopenta\[*a*\]indene-8a(1*H*)-carboxylate (**10h**) {#sec5.4.10}

White solid (99 mg, 81%). mp 145--147 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 7.84 (d, *J* = 8.2 Hz, 2H), 7.61--7.57 (m, 1H), 7.45--7.37 (m, 4H), 7.04 (d, *J* = 6.2 Hz, 1H), 6.27 (s, 1H), 6.03 (s, 1H), 5.39--5.29 (m, 1H), 4.67 (d, *J* = 10.0 Hz, 1H), 4.45 (d, *J* = 17.1 Hz, 1H), 3.61 (s, 3H), 3.35--3.21 (m, 2H), 2.61--2.45 (m, 5H). ^13^C NMR (126 MHz, CDCl~3~): δ 207.1, 178.1, 172.1, 144.7, 143.9, 137.6, 134.8, 134.1, 132.7, 130.2, 130.1, 127.6, 127.3, 124.7, 123.6, 117.6, 64.4, 62.5, 53.5, 47.9, 43.9, 21.7. IR (KBr): ν~max~ 3020, 2954, 1709, 1625, 1434, 1341, 1215, 1159, 1030, 896, 815, 744, 660 cm^--1^. MS (ESI): *m*/*z* 460 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~24~H~24~NO~5~S (M + H)^+^, 438.1370; found, 438.1389.

### Methyl 8-(*N*-((*tert*-Butyldimethylsilyl)oxy)-4-methylphenylsulfonamido)-2-oxo-3-phenyl-1,2,8,8a-tetrahydrocyclopenta\[*a*\]indene-8a-carboxylate (**10i**) {#sec5.4.11}

Pale yellow solid (75 mg, 58%). mp 195--197 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.75--7.70 (m, 2H), 7.48 (d, *J* = 7.8 Hz, 1H), 7.25--7.20 (m, 7H), 7.14--7.08 (m, 2H), 7.02--6.97 (m, 1H), 4.94 (s, 1H), 3.49 (s, 3H), 3.34 (d, *J* = 17.3 Hz, 1H), 2.53 (d, *J* = 17.3 Hz, 1H), 2.28 (s, 3H), 0.78 (s, 9H), 0.00 (s, 3H), −0.29 (s, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 204.9, 170.4, 169.9, 145.3, 142.6, 136.1, 133.7, 131.6, 130.9, 130.1, 129.9, 129.7, 129.4, 129.1, 128.9, 128.3, 123.4, 72.3, 64.7, 53.1, 48.4, 26.3, 21.8, 18.8, −4.1, −4.5. IR (KBr): ν~max~ 3054, 2930, 1710, 1365, 1171, 1044, 812, 669. MS (ESI): *m*/*z* 604 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~33~H~38~NO~6~SSi (M + H)^+^, 604.2189; found, 604.2205.

### Methyl 8-((*N*-Benzyl-4-methylphenyl)sulfonamido)-2-oxo-3-phenyl-2,8-dihydro-cyclopenta\[*a*\]indene-8a(1*H*)-carboxylate (**10j**) {#sec5.4.12}

White solid (107 mg, 79%). mp 194--196 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 7.77 (d, *J* = 8.3 Hz, 2H), 7.66 (d, *J* = 7.0 Hz, 1H), 7.50--7.38 (m, 5H), 7.34--7.27 (m, 6H), 7.25--7.15 (m, 3H), 6.41 (d, *J* = 7.4 Hz, 1H), 5.76 (s, 1H), 4.74 (dd, *J* = 40.8, 17.5 Hz, 2H), 3.69--3.59 (m, 1H), 3.02 (d, *J* = 17.6 Hz, 1H), 2.91 (s, 3H), 2.45 (s, 3H). ^13^C NMR (126 MHz, CDCl~3~): δ 204.7, 170.1, 167.7, 144.2, 138.8, 136.4, 134.5, 131.9, 128.9, 128.3, 128.2, 126.7, 126.2, 124.7, 123.8, 69.9, 66.6, 52.7, 49.7, 45.2, 21.6. IR (KBr): ν~max~ 3025, 2952, 1707, 1599, 1344, 1161, 1026, 758, 662 cm^--1^. MS (ESI): *m*/*z* 586 (M + Na)^+^; HRMS (ESI): *m*/*z* calcd for C~34~H~29~NO~5~S (M + Na)^+^, 564.1839; found, 564.1864.

### Methyl 2-(Hydroxy(2-(phenylethynyl)pyridin-3-yl)methyl)acrylate (**11**) {#sec5.4.13}

Brown liquid (800 mg, 68%). ^1^H NMR (500 MHz, CDCl~3~): δ 8.57 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.94 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.58--7.53 (m, 2H), 7.41--7.33 (m, 3H), 7.31 (dt, *J* = 15.9, 7.9 Hz, 1H), 6.37 (s, 1H), 6.14 (d, *J* = 5.0 Hz, 1H), 5.70 (s, 1H), 3.76 (s, 3H), 3.46 (d, *J* = 5.3 Hz, 1H). ^13^C NMR (126 MHz, CDCl~3~): δ 166.9, 149.2, 141.5, 140.6, 138.9, 134.6, 131.9, 129.2, 128.5, 127.5, 123.1, 122.1, 94.3, 86.5, 69.9, 52.2 IR (KBr): ν~max~ 3301, 2925, 2220, 1720, 1434, 1141, 757, 615. MS (ESI): *m*/*z* 294 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~18~H~16~NO~3~ (M + H)^+^, 294.1130; found, 294.1137.

### Methyl 2-(((*tert*-Butoxycarbonyl)oxy)(2-(phenylethynyl)pyridin-3-yl)methyl)acrylate (**12**) {#sec5.4.14}

Brown liquid (922 mg, 86%). ^1^H NMR (400 MHz, CDCl~3~): δ 8.59 (dd, *J* = 4.8, 1.7 Hz, 1H), 7.74 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.67--7.58 (m, 2H), 7.44--7.35 (m, 2H), 7.27 (q, *J* = 4.7 Hz, 2H), 7.07 (s, 1H), 6.53 (s, 1H), 5.83 (d, *J* = 0.7 Hz, 1H), 3.71 (s, 3H), 1.45 (s, 9H). ^13^C NMR (101 MHz, CDCl~3~): δ 165.1, 152.1, 149.7, 142.7, 137.9, 135.4, 134.7, 132.2, 129.2, 128.3, 128.2, 122.7, 122.1, 94.6, 86.2, 83.2, 72.9, 52.2, 27.7. IR (KBr): ν~max~ 2929, 1747, 1434, 1275, 1158, 758, 693 = MS (ESI): *m*/*z* 394(M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~23~H~24~NO~5~ (M + H)^+^, 394.1654; found, 394.1653.

### Methyl 2-((4-Methylphenylsulfonamido)(2-(phenylethynyl)pyridin-3-yl)methyl)acrylate (**13**) {#sec5.4.15}

Yellow liquid (89 mg, 79%). ^1^H NMR (500 MHz, CDCl~3~): δ 8.43 (dd, *J* = 4.7, 1.5 Hz, 1H), 7.72 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.64 (d, *J* = 8.3 Hz, 2H), 7.61--7.56 (m, 2H), 7.44--7.38 (m, 3H), 7.13--7.07 (m, 3H), 6.26 (s, 1H), 6.20 (d, *J* = 8.9 Hz, 1H), 5.91 (d, *J* = 8.9 Hz, 1H), 5.88 (s, 1H), 3.61 (s, 3H), 2.30 (s, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 165.7, 149.1, 143.5, 141.4, 137.4, 137.1, 136.2, 135.2, 132.1, 129.5, 129.4, 129.1, 128.6, 127.2, 122.7, 121.8, 94.7, 86.6, 56.4, 52.2, 21.4. IR = 3028, 2923, 2221, 1722, 1157, 1067, 755, 665. MS (ESI): *m*/*z* 447 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~25~H~22~N~2~O~4~S (M + H)^+^, 447.1379; found, 447.1352.

### Methyl 5-(4-Methylphenylsulfonamido)-7-oxo-8-phenyl-5,5a,6,7-tetrahydropentaleno\[1,2-*b*\]pyridine-5a-carboxylate (**14**) {#sec5.4.16}

Pale yellow solid (77 mg, 82%). 206--208 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 8.59 (d, *J* = 4.7 Hz, 1H), 8.13--8.02 (m, 2H), 7.82 (d, *J* = 8.2 Hz, 2H), 7.71 (d, *J* = 7.8 Hz, 1H), 7.49--7.31 (m, 6H), 6.52 (d, *J* = 10.6 Hz, 1H), 4.94 (d, *J* = 10.6 Hz, 1H), 3.60 (s, 3H), 2.67 (d, *J* = 17.2 Hz, 1H), 2.51--2.47 (m, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 205.1, 172.2, 163.8, 152.1, 150.7, 144.3, 141.3, 137.7, 136.6, 131.8, 130.6, 130.1, 129.7, 129.1, 127.9, 127.1, 125.8, 65.4, 61.6, 53.5, 46.2, 21.7. IR (KBr): ν~max~ 2925, 1712, 1598, 1405, 1262, 1161, 1083, 760. MS (ESI): *m*/*z* 474 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~26~H~22~N~2~O~5~SNa (M + Na)^+^, 497.1528; found, 497.1539.

### 8-Hydroxy-2-oxo-3-phenyl-1,2,8,8a-tetrahydrocyclopenta\[*a*\]indene-8a-carbonitrile (**16**) {#sec5.4.17}

Pale yellow solid (54 mg, 48%); mp 204--206 °C; ^1^H NMR (400 MHz, CDCl~3~): δ 7.74 (d, *J* = 7.8 Hz, 1H), 7.60 (dt, *J* = 14.8, 7.2 Hz, 2H), 7.54--7.42 (m, 5H), 7.38 (t, *J* = 7.2 Hz, 1H), 5.24 (d, *J* = 9.7 Hz, 1H), 3.28 (d, *J* = 17.9 Hz, 1H), 3.22 (d, *J* = 9.9 Hz, 1H), 3.09 (d, *J* = 17.9 Hz, 1H). ^13^C NMR (101 MHz, CDCl~3~): δ 202.3, 164.0, 146.3, 136.0, 133.4, 132.5, 129.9, 129.5, 129.3, 129.2, 128.6, 125.2, 125.0, 119.2, 79.5, 57.7, 44.5. IR (KBr): ν~max~ 3426, 3207, 2901, 2245, 1709, 1346, 1150, 757, 701. MS (ESI): *m*/*z* 288 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~19~H~14~NO~2~ (M + H)^+^, 288.1025; found, 288.1031

### (8*S*,8a*R*)-8-Hydroxy-3-phenyl-8,8a-dihydrocyclopenta\[*a*\]inden-2(1*H*)-one (**17**) {#sec5.4.18}

Pale Yellow solid (35 mg, 34%). mp 173--175 °C. ^1^H NMR (400 MHz, CDCl~3~): δ 7.62 (d, *J* = 7.7 Hz, 1H), 7.51 (d, *J* = 7.0 Hz, 1H), 7.47--7.36 (m, 5H), 7.34--7.29 (m, 1H), 7.23 (t, *J* = 7.5 Hz, 1H), 5.00 (t, *J* = 6.5 Hz, 1H), 3.48 (td, *J* = 6.6, 4.6 Hz, 1H), 2.95 (dd, *J* = 17.7, 6.8 Hz, 1H), 2.66 (dd, *J* = 17.7, 4.5 Hz, 1H), 2.39 (d, *J* = 7.3 Hz, 1H). ^13^C NMR (126 MHz, CDCl~3~): δ 205.8, 169.7, 148.6, 133.2, 132.9, 131.3, 130.0, 128.2, 127.7, 127.4, 123.8, 123.1, 77.2, 55.3, 39.6, 0.02. IR (KBr): ν~max~ 3456, 2924, 1711, 1639, 1350, 1120, 705 cm^--1^. MS (ESI): *m*/*z* 263 (M + H)^+^; HRMS (ESI): *m*/*z* calcd for C~18~H~15~O~2~ (M + H)^+^, 263.1072; found, 263.1077.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b02111](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b02111).Copies of ^1^H and ^13^C NMR spectra of all new compounds and X-ray analysis data for **6a**, **6b**, **10e,** and **16** ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b02111/suppl_file/ao8b02111_si_001.pdf))
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